Lessons learned during the development and transfer of technology related to a new Hib conjugate vaccine to emerging vaccine manufacturers

Vaccine

Volumn 32, Issue 33, 2014, Pages 4124-4130

  Hamidi, A ^a   Boog, C ^a   Jadhav, S ^b   Kreeftenberg, H ^a  

^a Institute for Translational Vaccinology (Intravacc)   (Netherlands)

^b Indus Biotech Private Limited   (India)

Author keywords

Haemophilus Influenzae type b; Lessons learned; Technology transfer developing countries vaccine manufacturers; Vaccine

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE VACCINE; HAEMOPHILUS VACCINE; VACCINE;

CHINA; DEVELOPING COUNTRY; FEASIBILITY STUDY; INDIA; INDONESIA; NONHUMAN; PATENT; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUALITY CONTROL; REVIEW; TECHNOLOGY; VACCINE PRODUCTION; BACTERIAL CAPSULE; ECONOMICS; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; MENINGITIS, HAEMOPHILUS; PHARMACEUTICS;

BACTERIAL CAPSULES; CHINA; DEVELOPING COUNTRIES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INDIA; INDONESIA; MENINGITIS, HAEMOPHILUS; TECHNOLOGY TRANSFER; TECHNOLOGY, PHARMACEUTICAL; VACCINES, CONJUGATE;

EID: 84903439081     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.023     Document Type: Review

References (43)

1. World Health Organization Global programme for vaccines and immunization: the WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 1998, 73:64-71.
2. Vaccine Preventable Deaths and the Global Immunization Vision and Strategy, 2006-2015 (CDC). http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5518a4.htm.
3. Duchêne M. Production, testing and perspectives of IPV and IPV combination vaccines: GSK biologicals' view. Biologicals 2006, 34:163-166.
4. Vidor E., Meschievitz C., Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 1997, 16(3):312-322.
5. Hendriksen C.F., van der Gun J.W., Marsman F.R., Kreeftenberg J.G. The use of the in vitro toxin binding inhibition (ToBI) test for the estimation of the potency of tetanus toxoid. Biologicals 1991, 19(1):23-29.
6. Hong H.A., Ke N.T., Nhon T.N., Thinh N.D., van der Gun J.W., Hendriks J.T., et al. Validation of the combined toxin-binding inhibition test for determination of neutralizing antibodies against tetanus and diphtheria toxins in a vaccine field study in Viet Nam. Bull World Health Organ 1996, 74(3):275-282.
7. World Bank Implementation Completion Rapport Rural Health and Preventive Medicine Project (Loan 2723-CHA/Credit 1713-CHA) Report No. 18893 1999, 37.
8. Kreeftenberg J.G., Hamidi A. World Health Organization meeting report on intellectual property rights and vaccines in developing countries, 2004. Annex 5: lessons learned in the transfer of Hib conjugate vaccine technology and the consequences for access to this vaccine in developing countries 2004.
9. Beurret M., Hamidi A., Kreeftenberg J. Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries. Vaccine 2012, 30(33):4897-4906.
10. Hendriks J., Holleman M., de Boer O., de Jong J., Luytjes W. An international technology platform for influenza vaccines. Vaccine 2011, 29(Suppl. 1):A8-A11.
11. Kreeftenberg H., van der Velden T., Kersten G., van der Heuvel N., de Bruijn M. Technology transfer of Sabin-IPV to new developing country markets. Biologicals 2006, 34(2):155-158.
12. Bakker W.A., Thomassen Y.E., van't Oever A.G., Westdijk J., van Oijen M.G., Sundermann L.C., et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011, 29(41):7188-7196.
13. Peeters C.C., Lagerman P.R., de Weers O., Oomen L.A., Hoogerhout P., Beurret M., et al. Polysaccharicb-conjugate vaccines. Methods Mol Med 1996, 4:111-133.
14. Hoogerhout P., Donders E.M., van Gaans-van den Brink J.A., Kuipers B., Brugghe H.F., van Unen L.M., et al. Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitides. Infect Immun 1995, 63(9):3473-3478.
15. Beuvery E.C., vd Kaaden A., Kanhai V., Leussink A.B. Physicochemical and immunological characterization of meningococcal group A polysaccharide-tetanus toxoid conjugates prepared by two methods. Vaccine 1983, 1(1):31-36.
16. Beuvery E.C., van Delft R.W., Miedema F., Kanhai V., Nagel J. Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice. Infect Immun 1983, 41(2):609-617.
17. WHO Expert Committee on Biological Standardization Forty-ninth report. Annex 1. Recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines. WHO technical report series 2000, 897:27-60.
18. WHO Expert Committee on Biological Standardization Forty-first report. Annex 1. Requirements for Haemophilus type b conjugate vaccines. WHO technical report series 1991, 814:1-27.
19. Annon. Haemophilus type b conjugate vaccine. Eur Pharmacopoeia 5.0 2005, 1(1219):662-664.
20. Schneerson R., Barrera O., Suton A., Robbins J.B. Preparation, characterization and immunogenicity of Haemophilus infuenzae type b polysaccharide-protein conjugates. J Exp Med 1980, 152:361-376.
21. Robbins J.B., Schneerson R., Szu S.C., Pozsgay V. Bacterial polysaccharide-protein conjugate vaccines. Pure Appl Chem 1999, 71(5):745-754.
22. Jennings HJ, Lugowski C, Canadian Patents & Development Ltd. C. Immunogenic polysaccharide-protein conjugates. US 4,356,170; 1981.
23. Gordon LK, Connaught Laboratories, Inc. (Swiftwater, PA). Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine. US 4,644,059; 1985.
24. Anderson PW, Eby RJ. The University of Rochester (Rochester, NY). Immunogenic conjugates. US 4,902,506; 1986.
25. Marburg S, Tolman RL, Kniskern PJ, Merck & Co., Inc. (Rahway, NJ). Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency. US 4,695,624; 1985.
26. Porro M, AMERICAN CYANAMID COMP&%Annotation-xml.content; (One Cyanamid Plaza, Wayne, NJ, 07470-8426, US). Improved oligosaccharide conjugate vaccines. EP 0,477,508; 1991.
27. Hoogerhout PN, Staat NL. Method of coupling polysaccharides to proteins. EP 0,848,011; 1996.
28. Mcmaster RP. Connaught laboratories, purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions. EP1140156; 1999.
29. Slaoui M, Hauser P. Smithkline Beecham Biolog (BE). Vaccines comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein. EP1,090,642; 1996.
30. Hamidi A, Beurret M, De Staat der N. Process for producing a capsular polysaccharide for use in conjugate vaccines. WO/2005/024038; 2004.
31. Hamidi A, Beurret M, De Staat der N. Process for producing a capsular polysaccharide for use in conjugate vaccines. US 7,582,459; 2004.
32. Hamidi A, Beurret M, De Staat der N. Process for producing a capsular polysaccharide for use in conjugate vaccines. EP 1,664,319; 2004.
33. Peltola H., Aavitsland P., Hansen K.G., Jónsdóttir K.E., Nøkleby H., Romanus V. Perspective a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. J Infect Dis 1999, 179:223-229.
34. Milstien J.B., Gaul P., Kaddar M. Access to vaccine technologies in developing countries. Brazil and India. Vaccine 2007, 25:7610-7619.
35. Frasch C.E., Preziosi M.P., LaForce F.M. Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM). Hum Vaccin Immunother 2012, 8(6):715-724.
36. Press release Merck, 2012-09-16. http://www.merck.com/licensing/our-partnership/Serum-collab pneumococcal-vaccine-partnership.html.
37. Ojo L.R., O'Loughlin R.E., Cohen A.L., Loo J.D., Edmond K.M., Shetty S.S., et al. Global use of Haemophilus influenzae type b conjugate vaccine. Vaccine 2010, 28:7117-7122.
38. Hajjeh R.A., Privor-Dumm L., Edmond K., O'Loughlin R., Shetty S., Griffiths U.K., et al. Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience. Vaccine 2010, 28:7123-7129.
39. World Health Organization The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 2006, 47:445-452.
40. GAVI Allicance Progress Report; 2011.
41. UNICEF Supplies and Logistics. Price data: http://www.unicef.org/supply/index_57476.html.
42. Milstien J.B., Gaul P., Kaddar M. Access to vaccine technologies in developing countries: Brazil and India. Vaccine 2007, 25:7610-7619.
43. World Health Organization Increasing access to vaccines through technology transfer and local production 2011, http://www.who.int/phi/publications/Increasing_Access_to_Vaccines_Through_Technology_Transfer.pdf.